Genedrive PLC's (LON:GDR) David Budd recaps on its two coronavirus test kits. The first, which was CE marked last week and they're in the process of launching, is a high-throughput lab-based PCR test which assesses whether someone's got an active infection. The second is a point-of-care version of the test which can be done outside of hospitals. Budd also discusses WHO approval received for its HCV test as well as new distribution arrangements for its infant deafness test.
29 May 20